Form 4: 5AM Ventures sells 200K Entrada shares at ~$9

5AM Ventures trimmed its Entrada Therapeutics stake, selling 200,000 shares on November 14, 2025 at $8.80–$9.023, and retains 2.96M shares directly.

Summary

• On 2025-11-14, 5AM Ventures V, L.P. sold 200,000 shares of Entrada Therapeutics, Inc. (TRDA) common stock.
• The reported weighted average sale price was $8.80, with trades executed between $8.80 and $9.023.
• Post-transaction direct holdings by 5AM Ventures V, L.P. are 2,963,066 shares.
• Additional indirect holdings total 1,093,313 shares held by 5AM Opportunities I, L.P.
• The sale implies an approximate 6.3% reduction in 5AM Ventures V, L.P.’s direct position (from ~3,163,066 to 2,963,066 shares).
• Reporting persons include 5AM Ventures V, L.P.; 5AM Partners V, LLC; 5AM Opportunities I, L.P.; 5AM Opportunities I (GP), LLC; Scott M. Rocklage; and Andrew J. Schwab.
• Reporting persons are 10% owners; certain individuals are managing members of relevant general partners; Dr. Kush Parmar is noted as a director and files separately.
• Signatures for the reporting persons are dated 2025-11-18.

Sentiment

Score: 4

Explanation: Insider sale by a >10% holder is a mild negative, but the sale size is modest relative to remaining holdings and does not imply a fundamental change.

Positives

• Large remaining ownership indicates continued exposure and alignment: 2,963,066 shares directly plus 1,093,313 shares indirectly.
• The divestment appears modest relative to direct holdings (~6.3% of the direct position).
• Sales were executed within a narrow price band near $9, suggesting orderly execution.

Negatives

• A >10% owner sold 200,000 shares, which can be perceived as a negative insider signal.
• Sales occurred around the sub-$10 level, potentially reinforcing a near-term supply overhang perception.

Future Outlook

No forward-looking statements or guidance are provided; this report solely discloses a change in beneficial ownership.

Management Comments

• Reporting persons undertake to provide full information on the number of shares sold at each separate price within the $8.80–$9.023 range upon request.
• 5AM Partners V, LLC, and certain individuals disclaim beneficial ownership of shares held by 5AM Ventures V, L.P., except to the extent of their pecuniary interest.
• 5AM Opportunities I (GP), LLC, and certain individuals disclaim beneficial ownership of shares held by 5AM Opportunities I, L.P., except to the extent of their pecuniary interest.
• Dr. Kush Parmar is a director of the issuer and files separate Section 16 reports.

Industry Context

Venture investors in development-stage biopharma frequently rebalance positions over time; modest trims that retain large residual stakes are common and do not necessarily signal a change in company fundamentals.

Comparison to Industry Standards

• Magnitude: A 200,000-share sale with ~2.96M direct shares retained is consistent with typical venture-backed biotech insider trims that keep a significant core position.
• Price dynamics: Execution in a tight band near $9 suggests planned or disciplined selling, similar to common practice among institutional holders managing liquidity and exposure.
• Ownership posture: Retaining a multi-million share stake aligns with industry norms where early investors maintain influence while gradually diversifying risk.

Stakeholder Impact

• Shareholders: Potentially mild negative sentiment from insider selling by a >10% owner.
• Market liquidity: Additional supply around ~$9 could marginally influence short-term trading dynamics.
• Employees, customers, suppliers, and creditors: No direct impact disclosed.

Key Dates

Recommendation

A modest insider sale by a significant holder without accompanying operational or financial updates warrants neutrality; the remaining large stake suggests no clear signal to buy or sell based solely on this event.

Keywords

Entrada Therapeutics, TRDA, Form 4, insider sale, beneficial ownership, 5AM Ventures, 10% owner, Scott Rocklage, Andrew Schwab, biotech, venture capital, Rule 16a